眾生藥業(002317.SZ):獲得來瑞特韋片(商品名:樂睿靈)澳門成藥登記證書
格隆匯8月9日丨眾生藥業(002317.SZ)公佈,近日,廣東眾生藥業股份有限公司控股子公司廣東眾生睿創生物科技有限公司(以下簡稱“眾生睿創”)獲得澳門特別行政區政府藥物監督管理局簽發的一類創新藥物來瑞特韋片(商品名:樂睿靈®)成藥登記證書。
來瑞特韋片(商品名:樂睿靈®)是公司自主研發的擁有全球自主知識產權的全球首款擬肽類3CL單藥抗新冠病毒一類新藥,2023年3月由國家藥品監督管理局按照藥品特別審批程序附條件批准上市,用於治療輕中度新型冠狀病毒感染(COVID-19)的成年患者,並已在同年經談判成功納入2023年國家醫保目錄乙類範圍。來瑞特韋片是公司抗病毒類的重要產品,本次獲批在澳門上市銷售,有望惠及更多新冠感染的患者,為廣大醫師和患者提供安全、有效的治療選擇。
來瑞特韋片不需要聯合肝藥酶抑制劑(CYP酶抑制劑)利托那韋,單藥治療即可顯著縮短新冠感染患者的臨牀恢復時間,顯著降低病毒載量,避免聯合利托那韋用藥可能產生的臨牀限制和安全性風險,為老年及合併基礎疾病等不能使用或限制使用利托那韋的新冠病毒感染患者提供可選擇的治療藥物。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.